We build the human data layer for drug development.

Machine learning is transforming how drugs are designed. Yet, nine out of ten drugs that enter human trials still fail. They are designed against aggregated patient data that captures static moments and largely misses the essential moments where human biology actually changes.

We own data collection at the source: the patient. Gather Bio controls a direct, continuous relationship with every patient living with chronic disease, and measures their biology when it changes: during an acute event, a treatment switch, or a hospitalization. The result is a consented, longitudinal molecular record of disease that exists nowhere else, built for machine learning from the first sample.

We believe every drug will one day be tested in a virtual patient before it is tested in a person. Those models will need data no hospital record or biobank holds today. We are gathering it.